Trial Profile
A Phase 3 Open-Label, Randomized, Multicenter Study of Imprime PGG in Combination With Cetuximab (Erbitux) in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Odetiglucan (Primary) ; Cetuximab
- Indications Colorectal cancer
- Focus Registrational; Therapeutic Use
- Acronyms PRIMUS
- Sponsors HiberCell
- 30 Jan 2017 Status changed from active, no longer recruiting to discontinued due to enrollment challenges resulting from changing treatment patterns in the use of cetuximab, No patients remain on study.
- 11 Oct 2016 Results (n=217) analysing relationship of anti-beta-glucan antibodies (ABA) and clinical outcomes, presented at the 41st European Society for Medical Oncology Congress.
- 09 Dec 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.